Novel MRGX2 Antagonists for Treating Diseases

ADVERTISEMENT RETURN TO ISSUEPREVPatent HighlightNEXTNovel MRGX2 Antagonists for Treating DiseasesRam W. Sabnis*Ram W. SabnisSmith, Gambrell & Russell LLP, 1105 West Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States*[email protected]More by Ram W. Sabnishttps://orcid.org/0000-0001-7289-0581Cite this: ACS Med. Chem. Lett. 2022, 13, 7, 1006–1007Publication Date (Web):June 21, 2022Publication History Received1 June 2022Published online21 June 2022Published inissue 14 July 2022https://pubs.acs.org/doi/10.1021/acsmedchemlett.2c00262https://doi.org/10.1021/acsmedchemlett.2c00262editorialACS PublicationsCopyright © Published 2022 by American Chemical Society. This publication is available under these Terms of Use. Request reuse permissions This publication is free to access through this site. Learn MoreArticle Views2753Altmetric-Citations-LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail PDF (790 KB) Get e-AlertscloseSUBJECTS:Anatomy,Antagonists,Diseases and disorders,Group 17 compounds,Receptors Get e-Alerts